A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

Psychiatry is often treated as separate to the rest of medicine. It's time to bring psychiatry into the era of precision medicine.

Developing treatments for neurological diseases presents a huge challenge for neuroscience companies within the biotech industry. The central nervous system (CNS) is extremely complex, and many ...

Chimeric antigen receptor (CAR)-T cell therapies have gone down in history as a major breakthrough in cancer treatment. Although more advanced cell therapies attempt to overcome the limitations of CAR ...

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech ...